Βv-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer

British Journal of Cancer

Volumn 107, Issue 5, 2012, Pages 823-830

  Christoph, D C ^a,b   Kasper, S ^a   Gauler, T C ^a,c   Loesch, C ^a   Engelhard, M ^a   Theegarten, D ^a   Poettgen, C ^a   Hepp, R ^a   Peglow, A ^a   Loewendick, H ^a   Welter, S ^c   Stamatis, G ^c   Hirsch, F R ^b   Schuler, M ^a,c   Eberhardt, W E E ^a,c   Wohlschlaeger, J ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

III V tubulin; biomarker; non small cell lung cancer; paclitaxel; vinorelbine

Indexed keywords

BETA TUBULIN; BETA TUBULIN 3; BETA TUBULIN 5; CARBOPLATIN; CISPLATIN; NAVELBINE; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CHEMORADIOTHERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAXOIDS; TRANSFECTION; TREATMENT OUTCOME; TUBULIN;

EID: 84865409211     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.324     Document Type: Article

References (35)

1. Azuma K, Sasada T, Kawahara A, Hattori S, Kinoshita T, Takamori S, Ichiki M, Imamura Y, Ikeda J, Kage M., Kuwano M, Aizawa H (2009a) Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 64: 565-573
2. Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H (2009b) Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64: 326-333
3. Banerjee A, Jensen-Smith H, Lazzell A, Prasad V, Elguezabal G, Hallworth Richard, Luduena RF (2008) Localization of betav tubulin in the cochlea and cultured cells with a novel monoclonal antibody. Cell Motil Cytoskeleton 65: 505-514 (Pubitemid 351794106)
4. Bhattacharya R, Cabral F (2004) A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol Biol Cell 15: 3123-3131 (Pubitemid 38850110)
5. Bhattacharya R, Cabral F (2009) Molecular basis for class V beta-tubulin effects on microtubule assembly and paclitaxel resistance. J Biol Chem 284: 13023-13032
6. Bhattacharya R, Frankfurter A, Cabral F (2008) A minor beta-tubulin essential for mammalian cell proliferation. Cell Motil Cytoskeleton 65: 708-720
7. Bhattacharya R, Yang H, Cabral F (2011) Class V b-tubulin alters dynamic instability and stimulates microtubule detachment from centrosomes. Mol Biol Cell 22: 1025-1034
8. Blade K, Menick DR, Cabral F (1999) Overexpression of class I, II or Ivb beta-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. J Cell Sci 113: 2213-2221 (Pubitemid 29355436)
9. Detterbeck FC, Boffa DJ, Tanoue LT (2009) The new lung cancer staging system. Chest 136: 260-271
10. Dumontet C, Isaac S, Souquet P-J, Bejui-Thivolet F, Pacheco Y, Peloux N, Frankfurter A, Luduena R, Perol M (2005) Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92: E25-E30
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247
12. Fawcett T (2004) ROC graphs: notes and practical considerations for researchers. ReCALL 31: 1-38
13. Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel Members (2011) Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO. Consensus Conference in Lung Cancer. Ann Oncol 22: 1507-1519
14. Felip E, Vilar E (2006) The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy. Ann Oncol 17: x108-x112 (Pubitemid 44541997)
15. Hari M, Yang H, Zeng C, Canizales M, Cabral F (2003) Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 56: 45-56 (Pubitemid 37059485)
16. Hiser L, Aggarwal A, Young R, Frankfurter A, Spano A, Correira JJ, Lobert S (2006) Comparison of beta-tubulin mRNA and protein levels in 12 human cancer cell lines. Cell Motil Cytoskeleton 63: 41-52 (Pubitemid 43157644)
17. Huber C, Bobek N, Kuball J, Thaler S, Hoffarth S, Huber C, Theobald M, Schuler M (2005) Inhibitors of apoptosis confer resistance to tumour suppression by adoptively transplanted cytotoxic T-lymphocytes in vitro and in vivo. Cell Death Differ 12: 317-325 (Pubitemid 40520683)
18. Jordan MA (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2: 1-17 (Pubitemid 34649866)
19. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265 (Pubitemid 38525281)
20. Kamath K, Wilson L, Cabral F, Jordan MA (2005) BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280: 12902-12907
21. Kang CH, Jang BG, Kim D-W, Chung DH, Kim YT, Jheon S, Sung S-W, Kim JH (2009) Differences in the expression profiles of excision repair crosscomplementation group 1, X-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival. J Thorac Oncol 4: 1307-1312
22. Kang CH, Jang BG, Kim D-W, Chung DH, Kim YT, Jheon S, Sung S-W, Kim JH (2010) The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum-and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 68: 478-483
23. Kasper S, Kindler T, Sonnenschein S, Breitenbuecher F, Boehmer FD, Huber C, Fischer T (2007) Cross-inhibition of interferon-induced signals by GM-CSF through a block in Stat1 activation. J Interferon Cytokine Res 27: 947-959 (Pubitemid 350223112)
24. Lin DY, Ying Z (1993) A simple nonparametric estimator of the bivariate survival function under univariate censoring. Biometrika 80: 573-581
25. Mariani M, Zannoni GF, Sioletic S, Sieber S, Martino C, Martinelli E, Coco C, Scambia G, Shahabi S, Ferlini C (2012) Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res 18: 1
26. Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y (2008) Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 62: 105-112
27. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB (2003) Oncogene 22: 7280-7295
28. Reguart N, Vinolas N, Casas F, Gimferrer JM, Agusti C, Molina R, Martin-Richard M, Sanchez-Reyes A, Gascon P (2004) Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results. Lung Cancer 45: 67-75 (Pubitemid 38757834)
29. Rosell R, Scagliotti G, Danenberg KD, Lord RVN, Bepler G, Novello S, Cooc J, Crino L, Sanchez JJ, Taron M, Boni C, De Marinis F, Tonato M, Marangalo M, Gozzelino F, Di Constanzo F, Rinaldi M, Salongo D, Stephens C (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548-3553 (Pubitemid 36765314)
30. Seve P, Mackey J, Isaac S, Tredan O, Souquet P-J, Perol M, Lai R, Voloch A, Dumontet C (2005) Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4: 2001-2007 (Pubitemid 43056983)
31. Spearman C (2010) The proof and measurement of association between two things. Int J Epidemiol 39: 1137-1150
32. Sullivan KF, Havercroft JC, Machlin PS, Cleveland DW (1986) Sequence and expression of the chicken beta 5-and beta 4-tubulin genes define a pair of divergent beta-tubulins with complementary patterns of expression. Mol Cell Biol 6: 4409-4418 (Pubitemid 17217382)
33. Verdier-Pinard P, Shahabi S, Wang F, Burd B, Xiao H, Goldberg GL, Orr GA, Horwitz SB (2005) Biochemistry 44: 15858-15870
34. Vilmar AC, Santoni-Rugiu E, Sorensen JB (2011) Class III b-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin Cancer Res 17: 5205-5214
35. Zalcman G, Levallet G, Bergot E, Antoine M, Creveuil C, Beau-Faller M, Brambilla E, Galateau-Salle F, Dumontet C, Morin F, Depierre A, Milleron B (2009) J Thorac Oncol 4: (abstract A 4.1)